newsfilter
← Latest News
GlobeNewswire·

Phase 2 Data from "ASTRAEUS" Trial of Mereo BioPharma's Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Lung Disease Presented at the 2023 American Thoracic Society International Conference

LONDON, May 23, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO), ("Mereo" or "the Company"), a clinical-stage biopharmaceutical company focused on rare diseases today announced that data from the Phase